Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study

Circulation

Volumn 128, Issue 11, 2013, Pages 1234-1243

  Sarode, Ravi ^a   Milling, Truman J ^b   Refaai, Majed A ^c   Mangione, Antoinette ^d   Schneider, Astrid ^e   Durn, Billie L ^d   Goldstein, Joshua N ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d CSL Behring LLC   (United States)

^e CSL BEHRING GMBH   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR; CILOSTAZOL; CLOPIDOGREL; PRASUGREL; PROTHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; HYPERVOLEMIA; INFUSION; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL HEMORRHAGE; PHASE 3 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSAL REACTION; THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; PLASMA; PROTHROMBIN COMPLEX CONCENTRATES; VITAMIN K ANTAGONIST;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIDOTES; BLOOD COAGULATION FACTORS; DRUG COMBINATIONS; EMERGENCIES; FACTOR IX; FACTOR VII; FACTOR X; FEMALE; HEMORRHAGE; HEMOSTATICS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; PROTHROMBIN; SINGLE-BLIND METHOD; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84884354180     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002283     Document Type: Article

References (39)

1. IMS data US National Prescription Audit; MAT (moving annual total) August 2011- July 2012
2. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6Suppl):257S-298S.
3. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010;170:1926-1933
4. Budnitz D, Lovegrove M, Shehab N, Richards C. Emergency hospitalizations for adverse events in older Americans. N Engl J Med. 2011; 365:2002-2012
5. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ,Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e152S- e184S.
6. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S,Makris M. Guidelines on oral coagulation with warfarin: Fourth edition. Br J Haematol. 2011;154:311-324
7. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e44S-e88S.
8. Bechtel BF, Nunez TC, Lyon JA, Cotton BA, Barrett TW. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: A structured literature review. Int J Emerg Med. 2011;4:40
9. Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand. 2011;55:507-516
10. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion. 2012;52:1673-1686; quiz 1673
11. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49:1171-1177
12. Vigué B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care. 2009;13:209
13. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care. 2011;15:201
14. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. Management of bleeding following major trauma: An updated European guideline. Crit Care. 2013;17:R76
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115
16. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-631
17. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest. 2008;133(6Suppl):160S-198S.
18. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M; The Recombinate Study Group. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83:2428-2435
19. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E,Mannucci P; ReFacto-AICE Study Group. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol. 2004;126:398-404
20. Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, Hannan MM. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost. 1996;75:30-35
21. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454
22. Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G. A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg. 2008;74:858-861
23. Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica. 2012;97:1501-1506
24. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: Experience in a large tertiary hospital. Crit Care. 2008;12:R105
25. Scott LJ. Prothrombin complex concentrate (Beriplex P/N). Drugs. 2009;69:1977-1984
26. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D,Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: A meta-analysis. Thromb Haemost. 2011;106:429-438
27. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R,Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205
28. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012:1-8
29. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52:160-165
30. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45:1113- 1118; discussion 1118
31. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, Hubmayr RD, Gajic O. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131:1308-1314
32. Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, Montori VM,Roback JD. The effect of plasma transfusion on morbidity and mortality: A systematic review and meta-analysis. Transfusion. 2010;50:1370-1383
33. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D,Yates S, Williamson LM; British Committee for Standards in Haematology,Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma,cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28
34. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C,McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H; SHOT Steering Group. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev. 2006;20:273-282
35. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;14:458-461
36. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465-1470
37. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77:477-480
38. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115:455-459
39. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol. 2008;83:137-143